EUR 0.39
(0.69%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 3 Million EUR | -49.28% |
2022 | 5.92 Million EUR | 758.4% |
2021 | 690.23 Thousand EUR | -12.13% |
2020 | 785.56 Thousand EUR | 24.3% |
2019 | 632 Thousand EUR | 49.7% |
2018 | 422.18 Thousand EUR | -66.01% |
2017 | 1.24 Million EUR | 100.49% |
2016 | 619.51 Thousand EUR | 20155.65% |
2015 | -3089.00 EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.18 Million EUR | 0.0% |
2023 Q4 | 1.14 Million EUR | 0.0% |
2023 FY | 7.68 Million EUR | 29.73% |
2023 Q2 | 3.99 Million EUR | 0.0% |
2022 Q4 | 2.9 Million EUR | 0.0% |
2022 FY | 5.92 Million EUR | 758.4% |
2022 Q2 | 3.43 Million EUR | 0.0% |
2021 Q2 | 1.76 Million EUR | 0.0% |
2021 FY | 690.23 Thousand EUR | -12.13% |
2021 Q4 | 2.56 Million EUR | 0.0% |
2020 Q4 | 397.72 Thousand EUR | 0.0% |
2020 FY | 785.56 Thousand EUR | 24.3% |
2020 Q2 | 388.07 Thousand EUR | 0.0% |
2019 FY | 632 Thousand EUR | 49.7% |
2019 Q4 | 378.55 Thousand EUR | 0.0% |
2019 Q2 | 253.44 Thousand EUR | 0.0% |
2018 FY | 422.18 Thousand EUR | -66.01% |
2018 Q4 | 220.72 Thousand EUR | 0.0% |
2018 Q2 | 201.45 Thousand EUR | 0.0% |
2017 FY | 1.24 Million EUR | 100.49% |
2017 Q4 | 1.01 Million EUR | 0.0% |
2017 Q1 | 2680.25 EUR | -99.28% |
2017 Q2 | 388.54 Thousand EUR | 14396.74% |
2016 Q2 | 367 Thousand EUR | 20970.76% |
2016 FY | 619.51 Thousand EUR | 20155.65% |
2016 Q1 | 1741.75 EUR | 0.0% |
2016 Q4 | 372.43 Thousand EUR | 0.0% |
2015 Q2 | 1790.00 EUR | 0.0% |
2015 Q3 | 1790.00 EUR | 0.0% |
2015 Q4 | 1741.75 EUR | -2.7% |
2015 FY | -3089.00 EUR | 0.0% |
2015 Q1 | 1790.00 EUR | 0.0% |
2014 Q4 | 1790.00 EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | 28.059% |
ABIVAX Société Anonyme | 127.37 Million EUR | 97.641% |
Adocia SA | 15.62 Million EUR | 80.773% |
Aelis Farma SA | 18.81 Million EUR | 84.032% |
Biophytis S.A. | 14.33 Million EUR | 79.034% |
Advicenne S.A. | 8.21 Million EUR | 63.421% |
genOway Société anonyme | 16.73 Million EUR | 82.047% |
IntegraGen SA | 5.35 Million EUR | 43.858% |
Medesis Pharma S.A. | 1.56 Million EUR | -92.064% |
Neovacs S.A. | 10.34 Million EUR | 70.948% |
NFL Biosciences SA | 4.37 Million EUR | 31.304% |
Plant Advanced Technologies SA | 2.76 Million EUR | -8.685% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -74.915% |
Sensorion SA | 27.05 Million EUR | 88.893% |
TME Pharma N.V. | 5.49 Million EUR | 45.334% |
Valbiotis SA | 9.86 Million EUR | 69.551% |
TheraVet SA | 1.64 Million EUR | -82.75% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 85.212% |
DBV Technologies S.A. | 89.4 Million EUR | 96.639% |
Genfit S.A. | 54.8 Million EUR | 94.517% |
GeNeuro SA | 14.35 Million EUR | 79.07% |
Innate Pharma S.A. | 64.57 Million EUR | 95.346% |
Inventiva S.A. | 120.18 Million EUR | 97.5% |
MaaT Pharma SA | 21.59 Million EUR | 86.087% |
MedinCell S.A. | 32.92 Million EUR | 90.872% |
Nanobiotix S.A. | 58.92 Million EUR | 94.9% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 87.261% |
Poxel S.A. | 28.76 Million EUR | 89.553% |
GenSight Biologics S.A. | 32.66 Million EUR | 90.799% |
Transgene SA | 31.23 Million EUR | 90.378% |
Valneva SE | 134.92 Million EUR | 97.773% |